NeoGenomics, Inc., a Florida-based company, is making waves in the field of cancer-focused testing laboratories with its expansive network spanning across the United States, Europe, and Asia. NeoGenomics is strategically divided into two main segments, Clinical Services, and Pharma Services, through which it offers testing services to a broad audience, including hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. The company's specialized services, such as cytogenetics testing, fluorescence in-situ hybridization testing, flow cytometry, and immunohistochemistry, among others, make it a preferred choice for clients looking for state-of-the-art testing services. Additionally, NeoGenomics offers molecular testing services that delve into DNA and RNA analysis, morphologic analysis, and testing services tailored to support oncology programs for pharmaceutical clients. Inivata Limited, a global leader in liquid biopsy technologies, is just one of NeoGenomics' strategic allies, with whom it has a strategic alliance agreement and laboratory services agreement. With a strong focus on further expanding its network and testing services, NeoGenomics is poised to set new standards in the world of cancer-focused testing laboratories.
Neo Performance Materials's ticker is NEO
The company's shares trade on the NASDAQ stock exchange
They are based in Fort Myers, Florida
There are 501-1000 employees working at Neo Performance Materials
It is neomaterials.com
Neo Performance Materials is in the Healthcare sector
Neo Performance Materials is in the Medical Laboratories & Research industry
The following five companies are Neo Performance Materials's industry peers: